Literature DB >> 6119558

Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension.

.   

Abstract

In all subjects of the Australian therapeutic trial in mild hypertension, mean pressures for the two screening visits were within the range 95-109 mm Hg for diastolic blood-pressure phase V(DBP) and less than 200 mm Hg for systolic blood-pressure (SBP). In the 1943 control (placebo) subjects mean blood-pressures fell from 158/102 mm Hg at the first screening visit to 144/91 mm Hg 3 years later. At that time pressures remained within the mild hypertension range in 32%, ahd risen above it in 12%, and had fallen below in 48%. Trial end-points (ischaemic heart disease or cerebrovascular accident) occurred in 8%. The outcome was related to the level of initial pressure but not to other characteristics measured at entry. The mean initial pressures of 22 subjects who experienced a cerebrovascular event were higher than those of a matched group with no hypertensive complications, but the 88 subjects who experienced ischaemic-heart-disease events had initial pressures similar to those in a matched control group. The trial end-point rate was related to the average DBP of subjects throughout the trial in those with average DBP greater than or equal to 95 mm Hg, and at those levels subjects on active treatment had a higher incidence than subjects of the placebo group with the same DBP level. For those with average DBP below 95 mm Hg the incidence of trial end-points was not related to blood-pressure level or treatment. 16% of placebo subjects in this mild hypertensive population had a mean DBP of less than 95 mm Hg at the first three visits. If this were taken as an indication to withhold drug treatment, 3 years later one-quarter of them (4% of all subjects) would be found to be hypertensive or to have experienced a trial end-point, and thus inappropriately untreated, while the other 12% would have pressures below 95 mm Hg and have had no trial end-point.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6119558

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  28 in total

Review 1.  Risks versus benefits of withdrawing antihypertensive therapy.

Authors:  H P Schobel; R E Schmieder; F H Messerli
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

Review 2.  Economic factors in the initiation of antihypertensive therapy.

Authors:  I Kawachi
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

3.  The treatment of hypertension: new lamps for old?

Authors:  J R Hampton
Journal:  Cardiovasc Drugs Ther       Date:  1991-12       Impact factor: 3.727

Review 4.  2014 hypertension recommendations from the eighth joint national committee panel members raise concerns for elderly black and female populations.

Authors:  Lawrence R Krakoff; Robert L Gillespie; Keith C Ferdinand; Icilma V Fergus; Ola Akinboboye; Kim A Williams; Mary Norine Walsh; C Noel Bairey Merz; Carl J Pepine
Journal:  J Am Coll Cardiol       Date:  2014-07-29       Impact factor: 24.094

Review 5.  What blood pressure levels should be treated?

Authors:  A Zanchetti
Journal:  Clin Investig       Date:  1992

6.  Overview and perspectives of antihypertensive treatment.

Authors:  A Zanchetti
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 7.  When is discontinuation of antihypertensive therapy indicated?

Authors:  R E Schmieder; J K Rockstroh
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

Review 8.  Experiences from hypertension trials--effects on stroke and coronary heart disease.

Authors:  G Berglund
Journal:  Drugs       Date:  1988       Impact factor: 9.546

9.  Mild hypertension: to treat or not to treat?

Authors:  Bernard Waeber; Helmy M Siragy
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

Review 10.  The J-curve in hypertension.

Authors:  John Cruickshank
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.